BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 68 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q3 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $23,349,858 | -43.2% | 8,135,839 | 0.0% | 0.38% | -35.8% |
Q2 2023 | $41,085,987 | +302.9% | 8,135,839 | +50.8% | 0.59% | +295.9% |
Q1 2023 | $10,198,136 | +4.9% | 5,395,839 | -0.1% | 0.15% | +14.7% |
Q4 2022 | $9,721,510 | +21.9% | 5,400,839 | +14.5% | 0.13% | +13.2% |
Q3 2022 | $7,972,000 | -31.3% | 4,717,113 | 0.0% | 0.11% | -30.5% |
Q2 2022 | $11,605,000 | +27.2% | 4,717,113 | +43.2% | 0.16% | +54.7% |
Q1 2022 | $9,122,000 | -50.6% | 3,293,000 | -4.9% | 0.11% | -44.2% |
Q4 2021 | $18,458,000 | -37.0% | 3,463,000 | 0.0% | 0.19% | -36.0% |
Q3 2021 | $29,297,000 | -30.6% | 3,463,000 | 0.0% | 0.30% | -27.9% |
Q2 2021 | $42,214,000 | -22.4% | 3,463,000 | +54.4% | 0.41% | -28.5% |
Q1 2021 | $54,415,000 | +21.0% | 2,243,000 | +59.9% | 0.58% | +11.8% |
Q4 2020 | $44,967,000 | +6.0% | 1,403,000 | 0.0% | 0.52% | -12.1% |
Q3 2020 | $42,413,000 | -28.3% | 1,403,000 | 0.0% | 0.59% | -30.0% |
Q2 2020 | $59,150,000 | +78.2% | 1,403,000 | +5.5% | 0.84% | +30.0% |
Q1 2020 | $33,184,000 | – | 1,330,000 | – | 0.64% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |